Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer.
*Anticarcinogenic Agents; Animal; Animals; Anti-Inflammatory Agents; Antioxidants; Biological Availability; Biological Markers; Carcinoma; Catechin/administration & dosage/analogs & derivatives; Chemoprevention; Disease Models; Hepatocellular – Physiopathology; Hepatocellular – Prevention and Control; Hepatocellular – Therapy; Human; Humans; In Vitro Studies; In Vivo Studies; Liver Neoplasms/*drug therapy/*prevention & control; Mice; Neoplasms – Prevention and Control; Nutrition; Outcomes (Health Care); Phenols – Therapeutic Use; Polyphenols/*administration & dosage/pharmacology; Tea – Therapeutic Use; Tea/*chemistry; Xenograft Model Antitumor Assays
The prophylactic and therapeutic properties of tea have been attributed to green tea catechins and black tea theaflavins besides several other polyphenolic compounds. Tea polyphenols possess potent antioxidant and antiinflammatory properties and modulate several signaling pathways. These biochemical facets of tea polyphenols are responsible for its anticancer properties. Several lethal cancers, such as liver cancer, develop within a background of oxidative stress and inflammation. Liver cancer, also known as hepatocellular carcinoma (HCC), has been shown to occur throughout the world including Asia, Africa, Western Europe, and the United States. Phytochemicals, such as tea polyphenols, provide an effective and promising alternative for the chemoprevention and treatment of HCC. In this article, we systematically review, for the first time, the effects of tea polyphenols in the preclinical in vitro and in vivo HCC models. The review also examines, in critical detail, the biochemical mechanisms involved in the chemopreventive and antineoplastic effects of tea polyphenols in hepatic cancer. Finally, we highlight the role of synergy, bioavailability and pharmacokinetics of tea polyphenols, current status of clinical trials, discuss future directions, and comment on the future challenges involved in the effective use of tea polyphenols for the prevention and management of liver cancer.
Darvesh Altaf S; Bishayee Anupam
Nutrition and cancer
2013
1905-07
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1080/01635581.2013.767367" target="_blank" rel="noreferrer noopener">10.1080/01635581.2013.767367</a>
Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma.
Anticarcinogenic Agents/*therapeutic use; Antineoplastic Agents – Therapeutic Use; Carcinoma; Hepatocellular – Drug Therapy; Hepatocellular – Prevention and Control; Hepatocellular/*drug therapy/*prevention & control; Humans; Liver Neoplasms – Drug Therapy; Liver Neoplasms – Prevention and Control; Liver Neoplasms/*drug therapy/*prevention & control; Resveratrol; Stilbenes – Therapeutic Use; Stilbenes/*therapeutic use
Hepatocellular carcinoma (HCC) is one of the most common cancers and lethal diseases in the world. Although the majority of HCC cases occur in developing countries of Asia and Africa, the prevalence of liver cancer has risen considerably in Japan, Western Europe as well as the United States. HCC most commonly develops in patients with chronic liver disease, the etiology of which includes viral hepatitis (B and C), alcohol, obesity, iron overload and dietary carcinogens, including aflatoxins and nitrosamines. The current treatment modalities, including surgical resection and liver transplantation, have been found to be mostly ineffective. Hence, there is an obvious critical need to develop alternative strategies for the chemoprevention and treatment of HCC. Oxidative stress as well as inflammation has been implicated in the development and progression of hepatic neoplasia. Using naturally occurring phytochemicals and dietary compounds endowed with potent antioxidant and antiinflammatory properties is a novel approach to prevent and control HCC. One such compound, resveratrol, present in grapes, berries, peanuts as well as red wine, has emerged as a promising molecule that inhibits carcinogenesis with a pleiotropic mode of action. This review examines the current knowledge on mechanism-based in vitro and in vivo studies on the chemopreventive and chemotherapeutic potential of resveratrol in liver cancer. Pre-clinical and clinical toxicity studies as well as pharmacokinetic data of resveratrol have also been highlighted in this review. Future directions and challenges involved in the use of resveratrol for the prevention and treatment of HCC are also discussed.
Bishayee Anupam; Politis Themos; Darvesh Altaf S
Cancer treatment reviews
2010
2010-02
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/j.ctrv.2009.10.002" target="_blank" rel="noreferrer noopener">10.1016/j.ctrv.2009.10.002</a>